Search

Your search keyword '"Uc, Ergun Y."' showing total 241 results
Start Over Author "Uc, Ergun Y."
241 results on '"Uc, Ergun Y."'

5. A pilot dose-finding study of terazosin in humans

Author

Schultz, Jordan L., primary, Gander, Phillip E., additional, Workman, Craig D., additional, Ponto, Laura L., additional, Cross, Stephen, additional, Nance, Christopher S., additional, Groth, Christopher L., additional, Taylor, Eric B., additional, Ernst, Sarah E., additional, Xu, Jia, additional, Uc, Ergun Y., additional, Magnotta, Vincent A., additional, Welsh, Michael J., additional, and Narayanan, Nandakumar S., additional

Published
2024
Full Text
View/download PDF

6. The human subthalamic nucleus transiently inhibits active attentional processes.

Author

Soh, Cheol, Hervault, Mario, Chalkley, Nathan H, Moore, Cathleen M, Rohl, Andrea, Zhang, Qiang, Uc, Ergun Y, Greenlee, Jeremy D W, and Wessel, Jan R

Subjects
DEEP brain stimulation, VISUAL evoked potentials, BASAL ganglia diseases, EVOKED potentials (Electrophysiology), RESPONSE inhibition
Abstract

The subthalamic nucleus (STN) of the basal ganglia is key to the inhibitory control of movement. Consequently, it is a primary target for the neurosurgical treatment of movement disorders like Parkinson's disease, where modulating the STN via deep brain stimulation (DBS) can release excess inhibition of thalamocortical motor circuits. However, the STN is also anatomically connected to other thalamocortical circuits, including those underlying cognitive processes like attention. Notably, STN-DBS can also affect these processes. This suggests that the STN may also contribute to the inhibition of non-motor activity and that STN-DBS may cause changes to this inhibition. Here we tested this hypothesis in humans. We used a novel, wireless outpatient method to record intracranial local field potentials (LFP) from STN DBS implants during a visual attention task (Experiment 1, n = 12). These outpatient measurements allowed the simultaneous recording of high-density EEG, which we used to derive the steady state visual evoked potential (SSVEP), a well established neural index of visual attentional engagement. By relating STN activity to this neural marker of attention (instead of overt behaviour), we avoided possible confounds resulting from STN's motor role. We aimed to test whether the STN contributes to the momentary inhibition of the SSVEP caused by unexpected, distracting sounds. Furthermore, we causally tested this association in a second experiment, where we modulated STN via DBS across two sessions of the task, spaced at least 1 week apart (n = 21, no sample overlap with Experiment 1). The LFP recordings in Experiment 1 showed that reductions of the SSVEP after distracting sounds were preceded by sound-related γ-frequency (>60 Hz) activity in the STN. Trial-to-trial modelling further showed that this STN activity statistically mediated the sounds' suppressive effect on the SSVEP. In Experiment 2, modulating STN activity via DBS significantly reduced these sound-related SSVEP reductions. This provides causal evidence for the role of the STN in the surprise-related inhibition of attention. These findings suggest that the human STN contributes to the inhibition of attention, a non-motor process. This supports a domain-general view of the inhibitory role of the STN. Furthermore, these findings also suggest a potential mechanism underlying some of the known cognitive side effects of STN-DBS treatment, especially on attentional processes. Finally, our newly established outpatient LFP recording technique facilitates the testing of the role of subcortical nuclei in complex cognitive tasks, alongside recordings from the rest of the brain, and in much shorter time than peri-surgical recordings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Digital driving data can track driving exposure and quality of life in Parkinson's disease.

Author

Jun Ha Chang, Bhatti, Danish, Uc, Ergun Y., Rizzo, Matthew, and Merickel, Jennifer

Subjects
PARKINSON'S disease, TRAFFIC safety, QUALITY of life, MOTOR vehicle driving, RISK exposure, MOVEMENT disorders, AUTOMOBILE driving, TEXT messages, INTELLIGENT transportation systems
Abstract

Objective: Parkinson's disease (PD) impairs motor and non-motor functions. Driver strategies to compensate for impairments, like avoiding driving in risky environments, may reduce on-road risk at the cost of decreasing driver mobility, independence, and quality of life (QoL). It is unclear how PD symptoms link to driving risk exposure, strategies, and QoL. We assessed associations between PD symptoms and driving exposure (1) overall, (2) in risky driving environments, and (3) in relationship to QoL. Methods: Twenty-eight drivers with idiopathic PD were assessed using the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and RAND 36-Item Short Form Health Survey (SF-36). Real-world driving was monitored for 1 month. Overall driving exposure (miles driven) and risky driving exposure (miles driven in higher risk driving environments) were assessed across PD symptom severity. High traffic, night, and interstate roads were considered risky environments. Results: 18,642 miles (30,001km) driven were collected. Drivers with PD with worse motor symptoms (MDS-UPDRS Part III) drove more overall (b=0.17, P<.001) but less in risky environments (night: b=-0.35, P<.001; interstate roads: b=-0.23, P<.001; high traffic: b=-0.14, P<.001). Worse non-motor daily activities symptoms (MDS-UPDRS Part I) did not affect overall driving exposure (b=-0.05, P=.43) but did affect risky driving exposure. Worse non-motor daily activities increased risk exposure to interstate (b=0.36, P<.001) and high traffic (b=0.09, P=.03) roads while reducing nighttime risk exposure (b=-0.15, P=.01). Daily activity impacts from motor symptoms (MDS-UPDRS Part II) did not affect distance driven. Reduced driving exposure (number of drives per day) was associated with worse physical health-related QoL (b=2.87, P=.04). Conclusions: Results provide pilot data revealing specific PD symptom impacts on driving risk exposure and QoL. Drivers with worse non-motor impairments may have greater risk exposure. In contrast, drivers with worse motor impairments may have reduced driver risk exposure. Reduced driving exposure may worsen physical health-related QoL. Results show promise for using driving to inform clinical care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Cognitive impairment in Parkinson’s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health

Author

Goldman, Jennifer G., Vernaleo, Beth A., Camicioli, Richard, Dahodwala, Nabila, Dobkin, Roseanne D., Ellis, Terry, Galvin, James E., Marras, Connie, Edwards, Jerri, Fields, Julie, Golden, Robyn, Karlawish, Jason, Levin, Bonnie, Shulman, Lisa, Smith, Glenn, Tangney, Christine, Thomas, Cathi A., Tröster, Alexander I., Uc, Ergun Y., Coyan, Noreen, Ellman, Crystal, Ellman, Mike, Hoffman, Charlie, Hoffman, Susan, and Simmonds, Don

Published
2018
Full Text
View/download PDF

25. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit

Author

Beal, Flint M., Oakes, David, Shoulson, Ira, Henchcliffe, Claire, Galpern, Wendy R., Haas, Richard, Juncos, Jorge L., Nutt, John G., Voss, Tiffini Smith, Ravina, Bernard, Shults, Clifford M., Helles, Karen, Snively, Victoria, Lew, Mark F., Griebner, Brian, Watts, Arthur, Gao, Shan, Pourcher, Emmanuelle, Bond, Louisette, Kompoliti, Katie, Agarwal, Pinky, Sia, Cherissa, Jog, Mandar, Cole, Linda, Sultana, Munira, Kurlan, Roger, Richard, Irene, Deeley, Cheryl, Waters, Cheryl H., Figueroa, Angel, Arkun, Ani, Brodsky, Matthew, Ondo, William G., Hunter, Christine B., Jimenez-Shahed, Joohi, Palao, Alicia, Miyasaki, Janis M., So, Julie, Tetrud, James, Reys, Liza, Smith, Katharine, Singer, Carlos, Blenke, Anita, Russell, David S., Cotto, Candace, Friedman, Joseph H., Lannon, Margaret, Zhang, Lin, Drasby, Edward, Kumar, Rajeev, Subramanian, Thyagarajan, Ford, Donna Stuppy, Grimes, David A., Cote, Diane, Conway, Jennifer, Siderowf, Andrew D., Evatt, Marian Leslie, Sommerfeld, Barbara, Lieberman, Abraham N., Okun, Michael S., Rodriguez, Ramon L., Merritt, Stacy, Swartz, Camille Louise, Martin, Wayne W. R., King, Pamela, Stover, Natividad, Guthrie, Stephanie, Watts, Ray L., Ahmed, Anwar, Fernandez, Hubert H., Winters, Adrienna, Mari, Zoltan, Dawson, Ted M., Dunlop, Becky, Feigin, Andrew S., Shannon, Barbara, Nirenberg, Melissa Jill, Ogg, Mattson, Ellias, Samuel A., Thomas, Cathi-Ann, Frei, Karen, Bodis-Wollner, Ivan, Glazman, Sofya, Mayer, Thomas, Hauser, Robert A., Pahwa, Rajesh, Langhammer, April, Ranawaya, Ranjit, Derwent, Lorelei, Sethi, Kapil D., Farrow, Buff, Prakash, Rajan, Litvan, Irene, Robinson, Annette, Sahay, Alok, Gartner, Maureen, Hinson, Vanessa K., Markind, Samuel, Pelikan, Melisa, Perlmutter, Joel S., Hartlein, Johanna, Molho, Eric, Evans, Sharon, Adler, Charles H., Duffy, Amy, Lind, Marlene, Elmer, Lawrence, Davis, Kathy, Spears, Julia, Wilson, Stephanie, Leehey, Maureen A., Hermanowicz, Neal, Niswonger, Shari, Shill, Holly A., Obradov, Sanja, Rajput, Alex, Cowper, Marilyn, Lessig, Stephanie, Song, David, Fontaine, Deborah, Zadikoff, Cindy, Williams, Karen, Blindauer, Karen A., Bergholte, Jo, Propsom, Clara Schindler, Stacy, Mark A., Field, Joanne, Mihaila, Dragos, Chilton, Mark, Uc, Ergun Y., Sieren, Jeri, Simon, David K., Kraics, Lauren, Silver, Althea, Boyd, James T., Hamill, Robert W., Ingvoldstad, Christopher, Young, Jennifer, Thomas, Karen, Kostyk, Sandra K., Wojcieszek, Joanne, Pfeiffer, Ronald F., Panisset, Michel, Beland, Monica, Reich, Stephen G., Cines, Michelle, Zappala, Nancy, Rivest, Jean, Zweig, Richard, Lumina, Pepper L., Hilliard, Colette Lynn, Grill, Stephen, Kellermann, Marye, Tuite, Paul, Rolandelli, Susan, Kang, Un Jung, Young, Joan, Rao, Jayaraman, Cook, Maureen M., Severt, Lawrence, and Boyar, Karyn

Published
2014
Full Text
View/download PDF

50. A Recommended Scale for Cognitive Screening in Clinical Trials of Parkinson’s Disease

Author

Litvan, Irene, Goldman, Jennifer, Tröster, Alexander I., Uc, Ergun Y., Frei, Karen, Levin, Bonnie, Amick, Melissa M., Gitelman, Darren, Brandt, Jason, Camicioli, Richard, Chou, Kelvin L., Simuni, Tanya, Marsh, Laura, Growdon, John, and Hurtig, Howard I.

Abstract

Cognitive impairment is common in Parkinson’s disease (PD). There is a critical need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is not on cognition.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results